摘要
目的 了解口服普萘洛尔治疗婴儿血管瘤中导致复发的因素。方法 对235例口服普萘洛尔治疗且已经停用普萘洛尔6个月的血管瘤患儿复发因素进行调查，使用单因素和多因素非条件logistic回归模型进行分析。结果 235例患儿停药6个月内复发66例，复发率28.1%（66/235），其中15例属于严重复发，占复发病例的22.7%（15/66）。复发的危险因素包括服药剂量为1.5 mg·kg^-1·d^-1（OR = 3.566，95% CI：1.306 ~ 9.739），首次服药时年龄＞8周（OR = 5.043，95% CI：1.248 ~ 20.376），服药疗程 ≤ 6个月（OR = 17.661，95% CI：4.899 ~ 63.665），停药时年龄＜1岁（OR = 6.089，95% CI：1.835 ~ 20.204）。结论 影响普萘洛尔治疗婴儿血管瘤复发的危险因素较多，应针对这些危险因素采取措施，降低复发率。
Objective To analyze factors associated with the relapse of propranolol-treated infantile hemangioma. Methods The clinical data were collected from 235 children with infantile hemangioma who had discontinued propranolol for 6 months, and retrospectively analyzed. Factors for the relapse of propranolol-treated infantile hemangioma were analyzed by univariate and multivariate uncon-ditional logistic regression analyses. Results Of 235 patients followed for 6 months after drug withdrawal, 66 （28.1%） were identified to have recurrence of infantile hemangioma, of whom, 15 （22.7%） had severe recurrence. The risk of recurrence was significantly increased in patients taking propranolol at a daily dosage of 1.5 mg/kg compared with those taking propranolol at a daily dosage of 2 mg/kg （OR = 3.566, 95% CI： 1.306 - 9.739）, in patients aged 〉 8 weeks at the initial drug treatment compared with those aged ≤ 8 weeks at the initial drug treatment （OR = 5.043, 95% CI： 1.248 - 20.376）, in patients with the course of medication ≤ 6 months compared with those with the course of medication 〉 6 months （OR = 17.661, 95% CI： 4.899 - 63.665）, as well as in patients aged 〈 1 year at drug withdrawal compared with those aged ≥ 1 year at drug withdrawal （OR = 6.089, 95% CI： 1.835 - 20.204）. Conclusion There are many risk factors associated with the relapse of propranolol-treated infantile hemangioma, so some measures aimed at these risk factors should be taken to reduce the recurrence rate.
作者
李丽
徐子刚
孙玉娟
燕丽
刘笑宇
马琳
Li Li Xu Zigang Sun Yujuan Yan Li Liu Xiaoyu Ma Lin(Department of Dermatology, Beijing Children＇s Hospital, Capital Medical University, Beijing 100045, China)
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2017年第2期77-80,共4页
Chinese Journal of Dermatology
基金
首都卫生发展科研专项基金（2016-2093）
北京市属医院科研培育计划（PX2016014）
